6 citations
,
October 2024 in “Journal of Family Medicine and Primary Care” This systematic review details monitoring and safety guidelines for primary care physicians regarding Janus kinase and tyrosine kinase 2 inhibitors used in treating inflammatory skin conditions, emphasizing their efficacy and the importance of updated knowledge due to associated box warnings and increasing use.
2 citations
,
September 2024 in “Expert Opinion on Drug Metabolism & Toxicology” This review highlights Ritlecitinib as a promising new oral treatment for Alopecia Areata, emphasizing its targeted action and potential efficacy, especially in adults and adolescents, though it notes the need for further real-world effectiveness and long-term safety studies.
5 citations
,
April 2019 in “Journal of Investigative Dermatology” This study found that oral JAK3 and TYK2/JAK1 inhibitors improved clinical outcomes in alopecia areata patients by reducing immune responses and enhancing hair keratin expression, with stronger effects in those with shorter disease duration.
15 citations
,
June 2020 in “Processes” This study suggests that the emulsion extract of brevilin A from Centipeda minima may stimulate hair regrowth in individuals with mild to moderate vertex balding by inhibiting JAK3.
April 2024 in “Journal of translational medicine” In this study, the researchers identified MJ04, a selective JAK3 inhibitor, as a promising candidate for promoting hair growth, demonstrating efficacy in both animal models and human hair follicle assays with a favorable safety and pharmacokinetic profile.